UBS Raises INNOVENT BIO (01801) Target Price to HK$120.1, Maintains "Buy" Rating

Stock News

Aug 01

UBS has issued a research report raising INNOVENT BIO's (01801) target price from HK$105.1 to HK$120.1 while maintaining a "Buy" rating. Assuming new indications for IBI363 are included, the bank has raised its peak sales forecasts for the drug in China and globally to RMB 5.7 billion and RMB 20.3 billion respectively.

INNOVENT BIO recently registered a Phase II clinical trial for IBI363. The bank believes this trial reflects the company's confidence in IBI363 as a next-generation immunotherapy cornerstone drug and is expected to expand the range of indications.

Additionally, industry data shows that the company's sales from January to May this year grew 33% year-over-year, maintaining strong momentum. The bank expects INNOVENT BIO's first-half revenue to grow 36% year-over-year and achieve break-even.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1128408650"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1128408650\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1128408650?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-01 14:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1128408650","market":"hk","top_or_hot":-1,"title":"UBS Raises INNOVENT BIO (01801) Target Price to HK$120.1, Maintains \"Buy\" Rating","media":"Stock News","content":"<p>UBS has issued a research report raising INNOVENT BIO's (01801) target price from HK$105.1 to HK$120.1 while maintaining a \"Buy\" rating. Assuming new indications for IBI363 are included, the bank has raised its peak sales forecasts for the drug in China and globally to RMB 5.7 billion and RMB 20.3 billion respectively.</p>\n<p>INNOVENT BIO recently registered a Phase II clinical trial for IBI363. The bank believes this trial reflects the company's confidence in IBI363 as a next-generation immunotherapy cornerstone drug and is expected to expand the range of indications.</p>\n<p>Additionally, industry data shows that the company's sales from January to May this year grew 33% year-over-year, maintaining strong momentum. The bank expects INNOVENT BIO's first-half revenue to grow 36% year-over-year and achieve break-even.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UBS Raises INNOVENT BIO (01801) Target Price to HK$120.1, Maintains \"Buy\" Rating</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUBS Raises INNOVENT BIO (01801) Target Price to HK$120.1, Maintains \"Buy\" Rating\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-08-01 14:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>UBS has issued a research report raising INNOVENT BIO's (01801) target price from HK$105.1 to HK$120.1 while maintaining a \"Buy\" rating. Assuming new indications for IBI363 are included, the bank has raised its peak sales forecasts for the drug in China and globally to RMB 5.7 billion and RMB 20.3 billion respectively.</p>\n<p>INNOVENT BIO recently registered a Phase II clinical trial for IBI363. The bank believes this trial reflects the company's confidence in IBI363 as a next-generation immunotherapy cornerstone drug and is expected to expand the range of indications.</p>\n<p>Additionally, industry data shows that the company's sales from January to May this year grew 33% year-over-year, maintaining strong momentum. The bank expects INNOVENT BIO's first-half revenue to grow 36% year-over-year and achieve break-even.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1128408650","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1128408650","pubTimestamp":1754029338,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"UBS has issued a research report raising INNOVENT BIO's (01801) target price from HK$105.1 to HK$120.1 while maintaining a \"Buy\" rating. Assuming new indications for IBI363 are included, the bank has...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","01801":"信达生物","BK1583":"高瓴概念","BK1589":"北水核心资产","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC"},"translate_title":"瑞银上调信达生物(01801)目标价至120.1港元维持“买入”评级","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01801":1},"content_text":"UBS has issued a research report raising INNOVENT BIO's (01801) target price from HK$105.1 to HK$120.1 while maintaining a \"Buy\" rating. Assuming new indications for IBI363 are included, the bank has raised its peak sales forecasts for the drug in China and globally to RMB 5.7 billion and RMB 20.3 billion respectively.\nINNOVENT BIO recently registered a Phase II clinical trial for IBI363. The bank believes this trial reflects the company's confidence in IBI363 as a next-generation immunotherapy cornerstone drug and is expected to expand the range of indications.\nAdditionally, industry data shows that the company's sales from January to May this year grew 33% year-over-year, maintaining strong momentum. The bank expects INNOVENT BIO's first-half revenue to grow 36% year-over-year and achieve break-even.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}